Cargando…
Bioinformatics roadmap for therapy selection in cancer genomics
Tumour heterogeneity is one of the main characteristics of cancer and can be categorised into inter‐ or intratumour heterogeneity. This heterogeneity has been revealed as one of the key causes of treatment failure and relapse. Precision oncology is an emerging field that seeks to design tailored tre...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627786/ https://www.ncbi.nlm.nih.gov/pubmed/35811332 http://dx.doi.org/10.1002/1878-0261.13286 |
_version_ | 1784823047393378304 |
---|---|
author | Jiménez‐Santos, María José García‐Martín, Santiago Fustero‐Torre, Coral Di Domenico, Tomás Gómez‐López, Gonzalo Al‐Shahrour, Fátima |
author_facet | Jiménez‐Santos, María José García‐Martín, Santiago Fustero‐Torre, Coral Di Domenico, Tomás Gómez‐López, Gonzalo Al‐Shahrour, Fátima |
author_sort | Jiménez‐Santos, María José |
collection | PubMed |
description | Tumour heterogeneity is one of the main characteristics of cancer and can be categorised into inter‐ or intratumour heterogeneity. This heterogeneity has been revealed as one of the key causes of treatment failure and relapse. Precision oncology is an emerging field that seeks to design tailored treatments for each cancer patient according to epidemiological, clinical and omics data. This discipline relies on bioinformatics tools designed to compute scores to prioritise available drugs, with the aim of helping clinicians in treatment selection. In this review, we describe the current approaches for therapy selection depending on which type of tumour heterogeneity is being targeted and the available next‐generation sequencing data. We cover intertumour heterogeneity studies and individual treatment selection using genomics variants, expression data or multi‐omics strategies. We also describe intratumour dissection through clonal inference and single‐cell transcriptomics, in each case providing bioinformatics tools for tailored treatment selection. Finally, we discuss how these therapy selection workflows could be integrated into the clinical practice. |
format | Online Article Text |
id | pubmed-9627786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96277862022-11-03 Bioinformatics roadmap for therapy selection in cancer genomics Jiménez‐Santos, María José García‐Martín, Santiago Fustero‐Torre, Coral Di Domenico, Tomás Gómez‐López, Gonzalo Al‐Shahrour, Fátima Mol Oncol Reviews Tumour heterogeneity is one of the main characteristics of cancer and can be categorised into inter‐ or intratumour heterogeneity. This heterogeneity has been revealed as one of the key causes of treatment failure and relapse. Precision oncology is an emerging field that seeks to design tailored treatments for each cancer patient according to epidemiological, clinical and omics data. This discipline relies on bioinformatics tools designed to compute scores to prioritise available drugs, with the aim of helping clinicians in treatment selection. In this review, we describe the current approaches for therapy selection depending on which type of tumour heterogeneity is being targeted and the available next‐generation sequencing data. We cover intertumour heterogeneity studies and individual treatment selection using genomics variants, expression data or multi‐omics strategies. We also describe intratumour dissection through clonal inference and single‐cell transcriptomics, in each case providing bioinformatics tools for tailored treatment selection. Finally, we discuss how these therapy selection workflows could be integrated into the clinical practice. John Wiley and Sons Inc. 2022-08-20 2022-11 /pmc/articles/PMC9627786/ /pubmed/35811332 http://dx.doi.org/10.1002/1878-0261.13286 Text en © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Jiménez‐Santos, María José García‐Martín, Santiago Fustero‐Torre, Coral Di Domenico, Tomás Gómez‐López, Gonzalo Al‐Shahrour, Fátima Bioinformatics roadmap for therapy selection in cancer genomics |
title | Bioinformatics roadmap for therapy selection in cancer genomics |
title_full | Bioinformatics roadmap for therapy selection in cancer genomics |
title_fullStr | Bioinformatics roadmap for therapy selection in cancer genomics |
title_full_unstemmed | Bioinformatics roadmap for therapy selection in cancer genomics |
title_short | Bioinformatics roadmap for therapy selection in cancer genomics |
title_sort | bioinformatics roadmap for therapy selection in cancer genomics |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627786/ https://www.ncbi.nlm.nih.gov/pubmed/35811332 http://dx.doi.org/10.1002/1878-0261.13286 |
work_keys_str_mv | AT jimenezsantosmariajose bioinformaticsroadmapfortherapyselectionincancergenomics AT garciamartinsantiago bioinformaticsroadmapfortherapyselectionincancergenomics AT fusterotorrecoral bioinformaticsroadmapfortherapyselectionincancergenomics AT didomenicotomas bioinformaticsroadmapfortherapyselectionincancergenomics AT gomezlopezgonzalo bioinformaticsroadmapfortherapyselectionincancergenomics AT alshahrourfatima bioinformaticsroadmapfortherapyselectionincancergenomics |